A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma
2011

Targeting Cancer Cells with a Special Nanocomplex

publication Evidence: moderate

Author Information

Author(s): Zhao Nianxi, Bagaria Hitesh G, Wong Michael S, Zu Youli

Primary Institution: Department of Pathology, the Methodist Hospital and the Methodist Hospital Research Institute

Hypothesis

Can a functional RNA nanocomplex be developed that selectively targets anaplastic large cell lymphoma (ALCL) cells and silences cancer genes?

Conclusion

The study found that the RNA nanocomplex effectively silenced the ALK gene in ALCL cells, leading to growth arrest and apoptosis.

Supporting Evidence

  • The nanocomplexes were stable for over 24 hours in culture medium.
  • CD30 aptamer probes selectively targeted ALCL cells.
  • Nanocomplexes led to a significant reduction in ALK gene expression in treated cells.
  • Treatment with the nanocomplex resulted in increased apoptosis in ALCL cells.

Takeaway

Researchers created a tiny delivery system that can specifically target and shut down cancer genes in certain lymphoma cells, helping to stop their growth.

Methodology

The study involved formulating a nanocomplex using ALK siRNA and a CD30 aptamer to target ALCL cells, followed by various assays to evaluate its effectiveness.

Limitations

The study primarily focused on in vitro results, which may not fully translate to in vivo conditions.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1477-3155-9-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication